ZSWIM2: A Potential Drug Target and Biomarker for Ubiquitin-Protein Ligase Enrichment

Target Name: ZSWIM2

NCBI ID: G151112

ZSWIM2

ZSWIM2: A Potential Drug Target and Biomarker for Ubiquitin-Protein Ligase Enrichment

Introduction

Ubiquitin-protein ligase (UPL) enzymes are involved in various cellular processes, including DNA repair, gene expression regulation, and cell signaling pathways. Dysregulation of UPLs has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZSWIM2, a member of the UPL family, has been identified as a potential drug target and biomarker for several reasons.

1. Overcoming the limitations of traditional therapeutics

The traditional approach to treating UPL-related diseases focuses on either supportive care or specific medications that target individual protein components. However, these approaches often have limited efficacy and may cause unintended side effects. ZSWIM2, as a potential drug target and biomarker, could offer a more targeted and effective approach to treating UPL-related diseases.

1. Compelling structural and functional evidence

The structure and function of ZSWIM2 have been extensively studied, providing compelling evidence for its potential as a drug target. ZSWIM2 is a 21-kDa protein that contains a N-terminal ubiquitin-like domain (ULD), a catalytic center, and a C -terminal domain responsible for N-terminal staffing. ZSWIM2 functions as a UPL, catalyzing the formation of a stable ubiquitin-protein ligase complex (UPLS) with its cognate protein substrate.

These studies have demonstrated ZSWIM2's unique catalytic properties, including its high catalytic efficiency, substrate specificity, and ability to enhance the stability of UPLS. ZSWIM2's ability to enhance UPLS stability could make it an attractive drug target for diseases where UPL function is disrupted.

1. Potential drug targets

ZSWIM2 has multiple potential drug targets, including the inhibition of its catalytic activity, the modulation of its stability, and the disruption of its role in cellular signaling pathways.

1. Inhibition of ZSWIM2 catalytic activity

The catalytic activity of ZSWIM2 could be inhibited by small molecules, peptides, or antibodies targeting its active site or N-terminal domain. This would prevent ZSWIM2 from forming UPLS with its cognate protein substrates, thus limiting its catalytic power.

1. Modulation of ZSWIM2 stability

Stable UPLS formation is critical for the function of ZSWIM2. Modulation of ZSWIM2 stability, either by increasing or decreasing its stability, could be a potential drug target. For example, small molecules or antibodies that enhance ZSWIM2 stability could be developed to treat diseases where UPL function is disrupted.

1. Disruption of ZSWIM2 role in signaling pathways

ZSWIM2 has been shown to participate in several cellular signaling pathways, including the TOR signaling pathway. Disruption of ZSWIM2's role in these pathways could lead to a reduction in cellular signaling and a decrease in disease severity. Targeting ZSWIM2 with small molecules or antibodies that specifically inhibit its role in these signaling pathways could be a potential drug strategy for treating UPL-related diseases.

Conclusion

ZSWIM2 is a promising drug target and biomarker for UPL-related diseases. Its unique catalytic properties, multiple potential drug targets, and involvement in cellular signaling pathways make it an attractive candidate for therapeutic intervention. Further research is needed to fully understand ZSWIM2's role in UPL -related diseases and to develop effective treatments.

Protein Name: Zinc Finger SWIM-type Containing 2

Functions: E3 ubiquitin-protein ligase involved in the regulation of Fas-, DR3- and DR4-mediated apoptosis. Functions in conjunction with the UBE2D1, UBE2D3 and UBE2E1 E2 ubiquitin-conjugating enzymes

The "ZSWIM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSWIM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets